Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evommune (EVMN) EPS (Weighted Average and Diluted) (2024 - 2025)

Evommune (EVMN) has disclosed EPS (Weighted Average and Diluted) for 2 consecutive years, with -$4.61 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) changed N/A to -$4.61 in Q4 2025 year-over-year; TTM through Dec 2025 was -$4.61, a N/A change, with the full-year FY2025 number at -$11.22, up 75.23% from a year prior.
  • EPS (Weighted Average and Diluted) was -$4.61 for Q4 2025 at Evommune, up from -$8.07 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$4.61 in Q4 2025 to a low of -$10.47 in Q3 2024.